Welcome to the Busath Lab


 


The influenza A virus became amantadine-resistant around the world in 2005. The video to the right provides one explanation for the mechanism of the change. The protein on the right is the new resistant structure and the one on the left is the amantadine-sensitive structure. In the simulation, amantadine is dragged through the channel. If not for the unnatural dragging force, the drug would normally get stuck about half-way through. In the video clip above, the amantadine blocks water from coming into the channel at that half-way point by turning down, whereas on the right it stays up-facing, dragging water, and protons, with it. These results have been published (see Figure 4 in the linked article).

 
Our Focus

  The Busath Lab focuses on two research projects, described in the next tab: Influenza Antiviral Development and Chronic Pain Mechanism and Alleviation. As a career biophysicist, Dr. Busath has, in past years, explored the origins of selectivity in rudimentary ion channels such as gramicidin, examined the protein channel function of botulinum toxin heavy chain, evaluated the role of general anesthetic and NSAID interaction with lipid monolayers and bilayers, and assessed proton transport through influenza A M2 channels. The two current research projects are natural outgrowths with broad missions. In the Influenza Anti-viral project, we hope to help protect the world against a pandemic arising from bird flu by developing inescapable blockers to the influenza proton channel. In the Chronic Pain project we hope to ascertain, with the help of brain imaging, the mechanism by which transcutaneous electrical stimulation can alleviate neuropathic pain to help lay the scientific foundation for drug-free relief of unnecessary chronic pain.




David D. Busath, M.D.

3019  LSB
Provo, UT 84602
(801) 422-8753
david_busath@byu.edu

Professor of Physiology and Biophysics

Publications
Curriculum Vitae
 



     


Donations to the Lab

   If you would like to make a tax-free donation, processed by LDS Philanthropies, to help support undergraduate and graduate research on either of these projects, please contact:

  Jim Welsh
  LDS Philanthropies Representative for the College of Life Sciences
  801-422-4447 (office), 801-473-7646 (cell), or  jim.welsh@byu.edu (email)


Inform Mr. Welsh that you would like to donate to the "Busath Influenza Drug Project" or the "Busath Chronic-Pain
" project and he will direct you how to make out and mail your donation. If you prefer to donate immediately, you can do so herebut you will need to search for and use the "Life Sciences Research - BYU" donation category and then notify Mr. Welsh for which of these two projects you want your donation to be used.


 
 




The influenza A virus became amantadine-resistant around the world in 2005. The video to the right provides one explanation for the mechanism of the change. The protein on the right is the new resistant structure and the one on the left is the amantadine-sensitive structure. In the simulation, amantadine is dragged through the channel. If not for the unnatural dragging force, the drug would normally get stuck about half-way through. Above, the amantadine blocks water from coming into the channel at that half-way point by turning down, whereas on the right it stays up-facing, dragging water, and protons, with it. These results have been published (see Figure 4 in the linked article).
The influenza A virus became amantadine-resistant around the world in 2005. The video to the right provides one explanation for the mechanism of the change. The protein on the right is the new resistant structure and the one on the left is the amantadine-sensitive structure. In the simulation, amantadine is dragged through the channel. If not for the unnatural dragging force, the drug would normally get stuck about half-way through. Above, the amantadine blocks water from coming into the channel at that half-way point by turning down, whereas on the right it stays up-facing, dragging water, and protons, with it. These results have been published (see Figure 4 in the linked article).
The influenza A virus became amantadine-resistant around the world in 2005. The video to the right provides one explanation for the mechanism of the change. The protein on the right is the new resistant structure and the one on the left is the amantadine-sensitive structure. In the simulation, amantadine is dragged through the channel. If not for the unnatural dragging force, the drug would normally get stuck about half-way through. Above, the amantadine blocks water from coming into the channel at that half-way point by turning down, whereas on the right it stays up-facing, dragging water, and protons, with it. These results have been published (see Figure 4 in the linked article).
The influenza A virus became amantadine-resistant around the world in 2005. The video to the right provides one explanation for the mechanism of the change. The protein on the right is the new resistant structure and the one on the left is the amantadine-sensitive structure. In the simulation, amantadine is dragged through the channel. If not for the unnatural dragging force, the drug would normally get stuck about half-way through. Above, the amantadine blocks water from coming into the channel at that half-way point by turning down, whereas on the right it stays up-facing, dragging water, and protons, with it. These results have been published (see Figure 4 in the linked article).